Xeris Biopharma Holdings
XERS
237 hedge funds and large institutions have $611M invested in Xeris Biopharma Holdings in 2026 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 99 increasing their positions, 55 reducing their positions, and 33 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 55
54% more call options, than puts
Call options by funds: $5.19M | Put options by funds: $3.37M
45% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 33
5% more funds holding
Funds holding: 225 → 237 (+12)
0.25% more ownership
Funds ownership: 60.76% → 61.01% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less capital invested
Capital invested by funds: $791M → $611M (-$180M)
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$12.7M |
| 2 |
Millennium Management
New York
|
+$9.33M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$7.43M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.93M |
| 5 |
VC
Voss Capital
Houston,
Texas
|
+$6.73M |
Top Sellers
XERS Hedge Fund Activity: Q1 2026 in Review
237 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2026, worth a combined $611M — down 23% from $791M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new XERS positions and 33 closed out — a net gain of 15 holders — while 99 added to existing stakes and 55 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $12.7M. The largest seller was Driehaus Capital Management, cutting an estimated $13.8M.
- 237 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2026, up from 225 in Q4 2025.
- Funds reported $611M of Xeris Biopharma Holdings stock for Q1 2026, down 23% quarter-over-quarter.
- 48 funds opened new Xeris Biopharma Holdings positions in Q1 2026 and 33 closed out, a net change of +15 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2026 was Armistice Capital, an estimated $12.7M added.
- The largest Xeris Biopharma Holdings seller in Q1 2026 was Driehaus Capital Management, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2026.